Welcome to our dedicated page for Aileron Therapeutics news (Ticker: ALRN), a resource for investors and traders seeking the latest updates and insights on Aileron Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aileron Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aileron Therapeutics's position in the market.
Aileron Therapeutics (NASDAQ: ALRN) has successfully closed a public offering of 10,162,059 shares of common stock, including an additional 1,071,149 shares exercised by underwriters, at a price of $1.10 per share. This offering generated gross proceeds of $11.2 million prior to deductions. The funds will be utilized for the clinical development of ALRN-6924 as a chemoprotective agent and for general corporate purposes. William Blair & Company acted as the sole book-running manager for the offering, which was conducted under an effective registration statement filed with the SEC.
Aileron Therapeutics (NASDAQ: ALRN) has priced an underwritten public offering of 9,090,910 shares at $1.10 per share, raising gross proceeds of $10 million. The offering includes a 30-day option for underwriters to purchase an additional 1,363,636 shares. The net proceeds will be allocated to the clinical development of ALRN-6924 and general corporate purposes. The offering closes on June 8, 2020, subject to customary conditions. The shares are offered under an effective SEC registration statement.
Aileron Therapeutics (NASDAQ: ALRN) has initiated a public offering of its common stock, with a potential 15% overallotment option for underwriters. Proceeds will support the clinical development of ALRN-6924 as a chemoprotective agent and for general corporate purposes. The offering follows an effective shelf registration statement with the SEC. William Blair & Company is the sole manager of the offering, which is subject to market conditions and may vary in size and terms.
Aileron Therapeutics (NASDAQ: ALRN) has expanded the dose optimization segment of its Phase 1b/2 clinical trial for ALRN-6924, aiming to protect small cell lung cancer (SCLC) patients from chemotherapy-induced toxicity. The first patient has been enrolled in an expansion cohort to evaluate a selected dose for chemoprotection against topotecan-related bone marrow toxicities. Aileron anticipates interim results by June 2020 and final data, including from this expansion, by Q4 2020. ALRN-6924 is a first-in-class dual MDM2/MDMX inhibitor targeting SCLC toxicities.